295 related articles for article (PubMed ID: 35802820)
21. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.
Bolck HA; Corrò C; Kahraman A; von Teichman A; Toussaint NC; Kuipers J; Chiovaro F; Koelzer VH; Pauli C; Moritz W; Bode PK; Rechsteiner M; Beerenwinkel N; Schraml P; Moch H
Eur Urol Focus; 2021 Jan; 7(1):152-162. PubMed ID: 31266731
[TBL] [Abstract][Full Text] [Related]
22. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
23. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma.
Slater AA; Alokail M; Gentle D; Yao M; Kovacs G; Maher ER; Latif F
Epigenetics; 2013 Mar; 8(3):252-67. PubMed ID: 23428843
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study of c-KIT (CD117) expression in renal cell carcinoma.
Ahmed EA; Youssif ME
J Egypt Natl Canc Inst; 2009 Jun; 21(2):121-32. PubMed ID: 21057563
[TBL] [Abstract][Full Text] [Related]
25. Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma.
Na JC; Kim JH; Kim SY; Gu YR; Jun DY; Lee HH; Yoon YE; Choi KH; Hong SJ; Han WK
Investig Clin Urol; 2020 Mar; 61(2):216-223. PubMed ID: 32158973
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of P2X4 receptor and mitochondrial metabolism in clear cell renal carcinoma models.
Rupert C; Dell' Aversana C; Mosca L; Montanaro V; Arcaniolo D; De Sio M; Bilancio A; Altucci L; Palinski W; Pili R; de Nigris F
J Exp Clin Cancer Res; 2023 May; 42(1):134. PubMed ID: 37231503
[TBL] [Abstract][Full Text] [Related]
27. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
29. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
Hong SH; Lee YJ; Jang EB; Hwang HJ; Kim ES; Son DH; Park SY; Moon HS; Yoon YE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203388
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive review of chromophobe renal cell carcinoma.
Garje R; Elhag D; Yasin HA; Acharya L; Vaena D; Dahmoush L
Crit Rev Oncol Hematol; 2021 Apr; 160():103287. PubMed ID: 33753250
[TBL] [Abstract][Full Text] [Related]
32. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system.
Miller CP; Fung M; Jaeger-Ruckstuhl CA; Xu Y; Warren EH; Akilesh S; Tykodi SS
Neoplasia; 2023 Dec; 46():100948. PubMed ID: 37944353
[TBL] [Abstract][Full Text] [Related]
34. Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms.
Lawrie CH; Armesto M; Fernandez-Mercado M; Arestín M; Manterola L; Goicoechea I; Larrea E; Caffarel MM; Araujo AM; Sole C; Sperga M; Alvarado-Cabrero I; Michal M; Hes O; López JI
J Mol Diagn; 2018 Jan; 20(1):34-45. PubMed ID: 29056573
[TBL] [Abstract][Full Text] [Related]
35. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
36. Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinoma.
Kazama A; Anraku T; Kuroki H; Shirono Y; Murata M; Bilim V; Ugolkov A; Saito K; Tomita Y
Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34468011
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
38. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
[TBL] [Abstract][Full Text] [Related]
39. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
[TBL] [Abstract][Full Text] [Related]
40. Three Dimensional Culture of Human Renal Cell Carcinoma Organoids.
Batchelder CA; Martinez ML; Duru N; Meyers FJ; Tarantal AF
PLoS One; 2015; 10(8):e0136758. PubMed ID: 26317980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
